Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mini-Review

New definition of remission in childhood acute lymphoblastic leukemia

Abstract

The extent of clearance of leukemic cells from the blood or bone marrow during the early phase of therapy is an independent prognostic factor in acute lymphoblastic leukemia (ALL). Several methods are available to measure the minimal residual disease (MRD) remaining after initial intensive chemotherapy. The most promising are flow cytometric detection of aberrant immunophenotypes and polymerase chain reaction analysis of clonal antigen-receptor gene rearrangements. When applied together, these techniques enable one to monitor MRD in virtually all cases of ALL. Patients who achieve an ‘immunologic’ or ‘molecular’ remission (ie leukemic involvement of <0.01% of nucleated bone marrow cells at the end of remission induction therapy) are predicted to have a better clinical outcome than patients whose remission is defined solely by morphologic criteria. in studies to date, patients with mrd at a level of 10−2 or more at the end of induction have fared almost as poorly as those with 5% blast cells in the bone marrow (ie induction failures). Sequential monitoring of MRD can improve the clinical utility of risk assessment still further. Additional studies are needed to determine the critical levels of MRD at various times of treatment and whether therapeutic intervention based on MRD findings can improve clinical outcome.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Reaman GH, Sather HN, Steinherz PG, Trigg ME, Tubergen DG, Uckun FM . Early response to therapy and outcome in childhood acute lymphoblastic leukemia. A review Cancer 1997 80 1717–1726

    Article  CAS  Google Scholar 

  2. Lilleyman JS . Clincial importance of speed of response to therapy in childhood lymphoblastic leukaemia Leuk Lymphoma 1998 31 501–506

    Article  CAS  Google Scholar 

  3. Silverman LB, Gelber RD, Young ML, Dalton VK, Barr RD, Sallan SE . Induction failure in acute lymphoblastic leukemia of childhood Cancer 1999 85 1395–1404

    Article  CAS  Google Scholar 

  4. Campana D, Pui C-H . Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance Blood 1995 85 1416–1434

    CAS  PubMed  Google Scholar 

  5. Foroni L, Harrison CJ, Hoffbrand AV, Potter MN . Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis Br J Haematol 1999 105 7–24

    CAS  PubMed  Google Scholar 

  6. Campana D, Coustan-Smith E . Detection of minimal residual disease in acute leukemia by flow cytometry Cytometry 1999 38 139–152

    Article  CAS  Google Scholar 

  7. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui C-H, Campana D . Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 1998 351 550–554

    Article  CAS  Google Scholar 

  8. van Dongen JJM, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig W-D, Basso G, de Bruijn MAC, Gazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WCJ, Riehm H, Bartram CR . Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 1998 352 1731–1738

    Article  CAS  Google Scholar 

  9. Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia New Engl J Med 1998 339 591–598

    Article  Google Scholar 

  10. Pui C-H, Evans WE . Acute lymphoblastic leukemia New Engl J Med 1998 339 605–615

    Article  CAS  Google Scholar 

  11. Neale GAM, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P, Behm FG, Pui C-H, Campana D . Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 1999 13 1221–1226

    Article  CAS  Google Scholar 

  12. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF . Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia New Engl J Med 1997 336 317–323

    Article  CAS  Google Scholar 

  13. Pongers-Willemse MJ, Verhagen OJHM, Tibbe GJM, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ . Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes Leukemia 1998 12 2006–2014

    Article  CAS  Google Scholar 

  14. Coustan-Smith E, Behm FG, Sancho J, Boyett JM, Hancock ML, Rivera GK, Rubnitz JE, Sandlund JT, Pui C-H, Campana D . Sequential monitoring of minimal residual disease in childhood acute lymphoblastic leukemia Blood 1999 94 (Suppl. 1) 626a

    Google Scholar 

  15. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS . Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy New Engl J Med 1998 338 1663–1671

    Article  CAS  Google Scholar 

  16. Chen J-S, Coustan-Smith E, Suzuki T, Neale GA, Pui C-H, Campana D . Identification of novel leukemia markers by comparative analysis of gene expression with DNA microarrays Blood 1999 94 (Suppl. 1) 657a

    Google Scholar 

Download references

Acknowledgements

This work was supported by grants CA 60419, CA 21765, and CA 20180 from the National Cancer Institute, by a Center of Excellence grant from the State of Tennessee, and by the American Lebanese Syrian Associated Charities (ALSAC).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pui, CH., Campana, D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 14, 783–785 (2000). https://doi.org/10.1038/sj.leu.2401780

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401780

Keywords

This article is cited by

Search

Quick links